{
  "nbformat": 4,
  "nbformat_minor": 0,
  "metadata": {
    "colab": {
      "provenance": [],
      "include_colab_link": true
    },
    "kernelspec": {
      "name": "python3",
      "display_name": "Python 3"
    },
    "language_info": {
      "name": "python"
    }
  },
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/rtdatasci/Python/blob/main/clinical_trials_query_hf.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "source": [
        "The primary objective of this Python script is to demonstrate a multi-step clinical trial metadata extraction pipeline using the smolagents library. Specifically, it aims to:\n",
        "\n",
        "Search for a Clinical Trial: Use an initial query (e.g., \"Ewing Sarcoma clinical trials completed phase 2\") to find an official study page on ClinicalTrials.gov and extract its NCT ID and Official Title. (Example found: NCT01583543).\n",
        "\n",
        "Preprocess Eligibility Criteria: Take a known clinical trial ID (NCT05275426) and use a Web Search Agent to find its eligibility criteria.\n",
        "\n",
        "Format the Data: Convert the raw eligibility text into a unified JSON format for easier machine processing and analysis."
      ],
      "metadata": {
        "id": "IDXHjiF9oCv4"
      }
    },
    {
      "cell_type": "markdown",
      "source": [
        "ğŸ› ï¸ Resources Used\n",
        "The script relies on the following key resources and tools:\n",
        "\n",
        "smolagents Library: This is the core framework used to create and run specialized agents (CodeAgent) for search and data processing tasks.\n",
        "\n",
        "Hugging Face API Token (HF_TOKEN): The agents use models from the Hugging Face Inference Client (InferenceClientModel) for their reasoning and code generation, which requires an API key stored as a Colab secret.\n",
        "\n",
        "WebSearchTool (Google Search): This tool, available to the agents, is used to query the web, primarily targeting the ClinicalTrials.gov website to locate study details and eligibility criteria.\n",
        "\n",
        "ClinicalTrials.gov: This is the ultimate data source, as the agents are instructed to specifically search for and parse the official study pages for clinical trial metadata."
      ],
      "metadata": {
        "id": "JA3BA6YgoFAw"
      }
    },
    {
      "cell_type": "code",
      "source": [
        "!pip install smolagents"
      ],
      "metadata": {
        "id": "XI7K4MZ3ssQo"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "metadata": {
        "id": "439ac362"
      },
      "source": [
        "from google.colab import userdata\n",
        "\n",
        "# Ensure you have your Hugging Face API token stored in Colab secrets under the name 'HF_TOKEN'\n",
        "HF_TOKEN = userdata.get('HF_TOKEN')"
      ],
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "GncWQLKtqCR3"
      },
      "outputs": [],
      "source": [
        "from smolagents import CodeAgent, InferenceClientModel, WebSearchTool\n",
        "\n",
        "# Tools available to all agents\n",
        "TOOLS = [WebSearchTool()]\n",
        "\n",
        "# --- 1. Clinical Trial Search Agent ---\n",
        "search_agent = CodeAgent(\n",
        "    tools=TOOLS,\n",
        "    model=InferenceClientModel(api_key=HF_TOKEN),\n",
        "    instructions=\"\"\"You are a clinical trial search agent.\n",
        "    Your task is to formulate a precise web search query to find the\n",
        "    official 'ClinicalTrials.gov' study page for the given condition.\n",
        "    The output should be the study's **NCT ID** (e.g., NCT05275426) and its **Official Title**.\"\"\"\n",
        ")\n",
        "\n",
        "# # --- Define the initial query ---\n",
        "# ingestion_query = \"Ewing Sarcoma clinical trials completed phase 2\"\n",
        "\n",
        "# # --- Run the first step (example) ---\n",
        "# # Note: You would run this and parse the output for the NCT ID.\n",
        "# # For this example, we will manually use the ID found on the open page.\n",
        "# nct_id = \"NCT05275426\"\n",
        "# trial_title = \"A Phase II Study of Oral CHK1 Inhibitor LY2880070 in Combination With Low-Dose Gemcitabine in Patients With Relapsed or Refractory Ewing Sarcoma, Ewing-like Sarcoma, and Desmoplastic Small Round Cell Tumor\""
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# --- Define the initial query ---\n",
        "ingestion_query = \"Ewing Sarcoma clinical trials completed phase 2\"\n",
        "\n",
        "ingestion_result = search_agent.run(ingestion_query)\n",
        "print(ingestion_result)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "3YQmsYY_tb7R",
        "outputId": "cc4b49d0-d9a4-4e61-b474-1fae82f99efd"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[38;2;212;183;2mâ•­â”€\u001b[0m\u001b[38;2;212;183;2mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[38;2;212;183;2m \u001b[0m\u001b[1;38;2;212;183;2mNew run\u001b[0m\u001b[38;2;212;183;2m \u001b[0m\u001b[38;2;212;183;2mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[38;2;212;183;2mâ”€â•®\u001b[0m\n",
              "\u001b[38;2;212;183;2mâ”‚\u001b[0m                                                                                                                 \u001b[38;2;212;183;2mâ”‚\u001b[0m\n",
              "\u001b[38;2;212;183;2mâ”‚\u001b[0m \u001b[1mEwing Sarcoma clinical trials completed phase 2\u001b[0m                                                                 \u001b[38;2;212;183;2mâ”‚\u001b[0m\n",
              "\u001b[38;2;212;183;2mâ”‚\u001b[0m                                                                                                                 \u001b[38;2;212;183;2mâ”‚\u001b[0m\n",
              "\u001b[38;2;212;183;2mâ•°â”€\u001b[0m\u001b[38;2;212;183;2m InferenceClientModel - Qwen/Qwen3-Next-80B-A3B-Thinking \u001b[0m\u001b[38;2;212;183;2mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[38;2;212;183;2mâ”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #d4b702; text-decoration-color: #d4b702\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ </span><span style=\"color: #d4b702; text-decoration-color: #d4b702; font-weight: bold\">New run</span><span style=\"color: #d4b702; text-decoration-color: #d4b702\"> â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span>                                                                                                                 <span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span> <span style=\"font-weight: bold\">Ewing Sarcoma clinical trials completed phase 2</span>                                                                 <span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span>                                                                                                                 <span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702\">â•°â”€ InferenceClientModel - Qwen/Qwen3-Next-80B-A3B-Thinking â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[38;2;212;183;2mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â” \u001b[0m\u001b[1;37mStep 1\u001b[0m\u001b[38;2;212;183;2m â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â” </span><span style=\"color: #c0c0c0; text-decoration-color: #c0c0c0; font-weight: bold\">Step 1</span><span style=\"color: #d4b702; text-decoration-color: #d4b702\"> â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              " â”€ \u001b[1mExecuting parsed code:\u001b[0m â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34msearch_query\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;255;70;137;48;2;39;40;34m=\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mEwing Sarcoma phase 2 completed clinical trial site:clinicaltrials.gov\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[48;2;39;40;34m                        \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34mresults\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;255;70;137;48;2;39;40;34m=\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34mweb_search\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m(\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34mquery\u001b[0m\u001b[38;2;255;70;137;48;2;39;40;34m=\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34msearch_query\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m)\u001b[0m\u001b[48;2;39;40;34m                                                                       \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34mprint\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m(\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34mresults\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m)\u001b[0m\u001b[48;2;39;40;34m                                                                                                 \u001b[0m  \n",
              " â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"> â”€ <span style=\"font-weight: bold\">Executing parsed code:</span> â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">search_query </span><span style=\"color: #ff4689; text-decoration-color: #ff4689; background-color: #272822\">=</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\"> </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"Ewing Sarcoma phase 2 completed clinical trial site:clinicaltrials.gov\"</span><span style=\"background-color: #272822\">                        </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">results </span><span style=\"color: #ff4689; text-decoration-color: #ff4689; background-color: #272822\">=</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\"> web_search(query</span><span style=\"color: #ff4689; text-decoration-color: #ff4689; background-color: #272822\">=</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">search_query)</span><span style=\"background-color: #272822\">                                                                       </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">print(results)</span><span style=\"background-color: #272822\">                                                                                                 </span>  \n",
              " â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[1mExecution logs:\u001b[0m\n",
              "## Search Results\n",
              "\n",
              "[Study Details | NCT06820957 - ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06820957)\n",
              "This phase II/III trial compares the effect of vincristine, irinotecan, and regorafenib (VIrR) in combination with \n",
              "vincristine, doxorubicin, cyclophosphamide (VDC), ifosfamide and etoposide (IE) to usual treatment with VDC/IE for \n",
              "the treatment of newly diagnosed Ewing  sarcoma or other round cell sarcomas that have spread from where they first\n",
              "started (primary site ) to other places in the body ...\n",
              "\n",
              "[Title: Phase 2 trial of palbociclib and ganitumab in pa ents with \n",
              "...](https://cdn.clinicaltrials.gov/large-docs/51/NCT04129151/Prot_SAP_001.pdf)\n",
              "This is a prospective, open-label, non-randomized, single arm two cohort phase  2  clinical  trial . Cohorts of \n",
              "patients with relapsed or refractory Ewing  sarcoma (Cohort A) or SDH-deficient GIST (Cohort B) will be enrolled \n",
              "and treated with a combination of palbociclib and ganitumab.\n",
              "\n",
              "[COVER PAGE - cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/21/NCT03495921/Prot_000.pdf)\n",
              "A Phase llb randomized open label trial (CL-PTL-121) comparing Vigil versus standard of care chemotherapy \n",
              "(gemcitabine/taxol) in metastatic, refractory or recurrent (â‰¥ 2 prior systemic treatment lines) Ewing's  sarcoma \n",
              "patients was initiated and enrolled the first patient 13 months ago.\n",
              "\n",
              "[DFMO Maintenance for Patients With Relapsed/ Refractory Ewing Sarcoma \n",
              "...](https://clinicaltrials.gov/study/NCT06892678)\n",
              "Outcome of patients with relapsed or progressive Ewing  sarcoma enrolled on cooperative group phase  2  clinical  \n",
              "trials : A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 Dec;68 (12):e29333. doi: \n",
              "10.1002/pbc.29333. Epub 2021 Sep 8.\n",
              "\n",
              "[INTRODUCTION - cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/70/NCT01610570/ICF_000.pdf)\n",
              "STUDY TITLE: Brigitte Widemann, M.D. Phase I/II Trial of Mithramycin in Children and Adults with Refractory \n",
              "Extracranial Solid Tumors ( Phase I) or Ewing  Sarcoma and EWS-FLI1 Fusion Transcript ( Phase II) Date posted to \n",
              "web: 01/22/15 Continuing Review Approved by the IRB on 01/12/15 Amendment Approved by the IRB on 12/24/14 (E) Phase\n",
              "I Portion\n",
              "\n",
              "[Olaparib in Adults With Recurrent/ Metastatic Ewing's \n",
              "Sarcoma](https://clinicaltrials.gov/study/NCT01583543?tab=results)\n",
              " Phase II study of olaparib in patients with refractory Ewing  sarcoma following failure of standard chemotherapy. \n",
              "BMC Cancer. 2014 Nov 5;14:813. doi: 10.1186/1471-2407-14-813.\n",
              "\n",
              "[Amendment - cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/70/NCT01610570/Prot_SAP_002.pdf)\n",
              " Phase II portion of this trial to: evaluate if mithramycin inhibits NR0B1 in tumor tissue and determine changes in\n",
              "gene expression signature pre-treatment and at steady state on day +4 of treatment in patients â‰¥ 18 years old with \n",
              "Ewing  sarcoma and EWS/FLI1 fusion transcript with disease amenable to percutaneous biopsy.\n",
              "\n",
              "[Studio clinico osservazionale per il trattamento dell' osteosarcoma non \n",
              "...](https://cdn.clinicaltrials.gov/large-docs/97/NCT03542097/Prot_000.pdf)\n",
              "Four irinotecan plus temozolomide in relapsed Ewing  sarcoma studies were published, as reported in Table 1. In all\n",
              "studies irinotecan was given in prolonged infusion, at a low dosage, with a 4-fold irinotecan dose difference, in a\n",
              "total number of 65 patients. In the first phase I study 14 patients were evaluable, reporting 1 CR, 3 PRs, and 4 \n",
              "SDs.\n",
              "\n",
              "[Official Title: A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion \n",
              "...](https://cdn.clinicaltrials.gov/large-docs/05/NCT02712905/SAP_001.pdf)\n",
              "For Ewing's  sarcoma subjects in the FAS, time since advanced/metastatic diagnosis, stage at initial diagnosis, \n",
              "grade at initial diagnosis, sites of disease at initial diagnosis, current stage of disease, current sites of \n",
              "disease, cytogenetics status, CDKN2A status, TP53 status, and STAG2 status will be summarized and listed.\n",
              "\n",
              "[\"An open-label phase II single-centre study investigating the safety \n",
              "...](https://cdn.clinicaltrials.gov/large-docs/05/NCT03725605/Prot_000.pdf)\n",
              "\"An open-label phase II single-centre study investigating the safety and efficacy of LTX-315 and adoptive T-cell \n",
              "therapy in patients with advanced/metastatic soft tissue sarcoma \" Clinical  Trial Protocol\n",
              "\n",
              "Out: None\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"font-weight: bold\">Execution logs:</span>\n",
              "## Search Results\n",
              "\n",
              "[Study Details | NCT06820957 - ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT06820957)\n",
              "This phase II/III trial compares the effect of vincristine, irinotecan, and regorafenib (VIrR) in combination with \n",
              "vincristine, doxorubicin, cyclophosphamide (VDC), ifosfamide and etoposide (IE) to usual treatment with VDC/IE for \n",
              "the treatment of newly diagnosed Ewing  sarcoma or other round cell sarcomas that have spread from where they first\n",
              "started (primary site ) to other places in the body ...\n",
              "\n",
              "[Title: Phase 2 trial of palbociclib and ganitumab in pa ents with \n",
              "...](https://cdn.clinicaltrials.gov/large-docs/51/NCT04129151/Prot_SAP_001.pdf)\n",
              "This is a prospective, open-label, non-randomized, single arm two cohort phase  2  clinical  trial . Cohorts of \n",
              "patients with relapsed or refractory Ewing  sarcoma (Cohort A) or SDH-deficient GIST (Cohort B) will be enrolled \n",
              "and treated with a combination of palbociclib and ganitumab.\n",
              "\n",
              "[COVER PAGE - cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/21/NCT03495921/Prot_000.pdf)\n",
              "A Phase llb randomized open label trial (CL-PTL-121) comparing Vigil versus standard of care chemotherapy \n",
              "(gemcitabine/taxol) in metastatic, refractory or recurrent (â‰¥ 2 prior systemic treatment lines) Ewing's  sarcoma \n",
              "patients was initiated and enrolled the first patient 13 months ago.\n",
              "\n",
              "[DFMO Maintenance for Patients With Relapsed/ Refractory Ewing Sarcoma \n",
              "...](https://clinicaltrials.gov/study/NCT06892678)\n",
              "Outcome of patients with relapsed or progressive Ewing  sarcoma enrolled on cooperative group phase  2  clinical  \n",
              "trials : A report from the Children's Oncology Group. Pediatr Blood Cancer. 2021 Dec;68 (12):e29333. doi: \n",
              "10.1002/pbc.29333. Epub 2021 Sep 8.\n",
              "\n",
              "[INTRODUCTION - cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/70/NCT01610570/ICF_000.pdf)\n",
              "STUDY TITLE: Brigitte Widemann, M.D. Phase I/II Trial of Mithramycin in Children and Adults with Refractory \n",
              "Extracranial Solid Tumors ( Phase I) or Ewing  Sarcoma and EWS-FLI1 Fusion Transcript ( Phase II) Date posted to \n",
              "web: 01/22/15 Continuing Review Approved by the IRB on 01/12/15 Amendment Approved by the IRB on 12/24/14 (E) Phase\n",
              "I Portion\n",
              "\n",
              "[Olaparib in Adults With Recurrent/ Metastatic Ewing's \n",
              "Sarcoma](https://clinicaltrials.gov/study/NCT01583543?tab=results)\n",
              " Phase II study of olaparib in patients with refractory Ewing  sarcoma following failure of standard chemotherapy. \n",
              "BMC Cancer. 2014 Nov 5;14:813. doi: 10.1186/1471-2407-14-813.\n",
              "\n",
              "[Amendment - cdn.clinicaltrials.gov](https://cdn.clinicaltrials.gov/large-docs/70/NCT01610570/Prot_SAP_002.pdf)\n",
              " Phase II portion of this trial to: evaluate if mithramycin inhibits NR0B1 in tumor tissue and determine changes in\n",
              "gene expression signature pre-treatment and at steady state on day +4 of treatment in patients â‰¥ 18 years old with \n",
              "Ewing  sarcoma and EWS/FLI1 fusion transcript with disease amenable to percutaneous biopsy.\n",
              "\n",
              "[Studio clinico osservazionale per il trattamento dell' osteosarcoma non \n",
              "...](https://cdn.clinicaltrials.gov/large-docs/97/NCT03542097/Prot_000.pdf)\n",
              "Four irinotecan plus temozolomide in relapsed Ewing  sarcoma studies were published, as reported in Table 1. In all\n",
              "studies irinotecan was given in prolonged infusion, at a low dosage, with a 4-fold irinotecan dose difference, in a\n",
              "total number of 65 patients. In the first phase I study 14 patients were evaluable, reporting 1 CR, 3 PRs, and 4 \n",
              "SDs.\n",
              "\n",
              "[Official Title: A Phase 1/2, Open-Label, Dose-Escalation/Dose-Expansion \n",
              "...](https://cdn.clinicaltrials.gov/large-docs/05/NCT02712905/SAP_001.pdf)\n",
              "For Ewing's  sarcoma subjects in the FAS, time since advanced/metastatic diagnosis, stage at initial diagnosis, \n",
              "grade at initial diagnosis, sites of disease at initial diagnosis, current stage of disease, current sites of \n",
              "disease, cytogenetics status, CDKN2A status, TP53 status, and STAG2 status will be summarized and listed.\n",
              "\n",
              "[\"An open-label phase II single-centre study investigating the safety \n",
              "...](https://cdn.clinicaltrials.gov/large-docs/05/NCT03725605/Prot_000.pdf)\n",
              "\"An open-label phase II single-centre study investigating the safety and efficacy of LTX-315 and adoptive T-cell \n",
              "therapy in patients with advanced/metastatic soft tissue sarcoma \" Clinical  Trial Protocol\n",
              "\n",
              "Out: None\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[2m[Step 1: Duration 23.52 seconds| Input tokens: 2,161 | Output tokens: 3,237]\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">[Step 1: Duration 23.52 seconds| Input tokens: 2,161 | Output tokens: 3,237]</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[38;2;212;183;2mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â” \u001b[0m\u001b[1;37mStep 2\u001b[0m\u001b[38;2;212;183;2m â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â” </span><span style=\"color: #c0c0c0; text-decoration-color: #c0c0c0; font-weight: bold\">Step 2</span><span style=\"color: #d4b702; text-decoration-color: #d4b702\"> â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              " â”€ \u001b[1mExecuting parsed code:\u001b[0m â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34mfinal_answer\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m(\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mNCT01583543: Phase II Study of Olaparib in Patients With Refractory Ewing Sarcoma Following \u001b[0m\u001b[48;2;39;40;34m     \u001b[0m  \n",
              "  \u001b[38;2;230;219;116;48;2;39;40;34mFailure of Standard Chemotherapy\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m)\u001b[0m\u001b[48;2;39;40;34m                                                                             \u001b[0m  \n",
              " â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"> â”€ <span style=\"font-weight: bold\">Executing parsed code:</span> â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">final_answer(</span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"NCT01583543: Phase II Study of Olaparib in Patients With Refractory Ewing Sarcoma Following </span><span style=\"background-color: #272822\">     </span>  \n",
              "  <span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">Failure of Standard Chemotherapy\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">)</span><span style=\"background-color: #272822\">                                                                             </span>  \n",
              " â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"></pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[1;38;2;212;183;2mFinal answer: NCT01583543: Phase II Study of Olaparib in Patients With Refractory Ewing Sarcoma Following Failure \u001b[0m\n",
              "\u001b[1;38;2;212;183;2mof Standard Chemotherapy\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #d4b702; text-decoration-color: #d4b702; font-weight: bold\">Final answer: NCT01583543: Phase II Study of Olaparib in Patients With Refractory Ewing Sarcoma Following Failure </span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702; font-weight: bold\">of Standard Chemotherapy</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[2m[Step 2: Duration 22.94 seconds| Input tokens: 5,835 | Output tokens: 6,902]\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">[Step 2: Duration 22.94 seconds| Input tokens: 5,835 | Output tokens: 6,902]</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "NCT01583543: Phase II Study of Olaparib in Patients With Refractory Ewing Sarcoma Following Failure of Standard Chemotherapy\n"
          ]
        }
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "# --- 2. Eligibility Preprocessing Agent ---\n",
        "nct_id = \"NCT05275426\"\n",
        "trial_title = \"A Phase II Study of Oral CHK1 Inhibitor LY2880070 in Combination With Low-Dose Gemcitabine in Patients With Relapsed or Refractory Ewing Sarcoma, Ewing-like Sarcoma, and Desmoplastic Small Round Cell Tumor\"\n",
        "\n",
        "preprocessing_agent = CodeAgent(\n",
        "    tools=TOOLS,\n",
        "    model=InferenceClientModel(api_key=HF_TOKEN),\n",
        "    instructions=f\"\"\"You are a clinical trials metadata preprocessing agent.\n",
        "    Your task is to take a ClinicalTrials.gov ID (e.g., {nct_id}) and use your\n",
        "    WebSearchTool to find the associated study page, focusing on the\n",
        "    **'Participation Criteria'** section.\n",
        "\n",
        "    Your goal is to parse this raw text and convert it into a **unified JSON format**.\n",
        "    You must extract the information from the 'Eligibility Criteria' section.\n",
        "\n",
        "    Use the following specific JSON schema for the output:\n",
        "    {{\n",
        "      \"clinical_trials_id\": \"{nct_id}\",\n",
        "      \"title\": \"{trial_title}\",\n",
        "      \"ages_eligible_for_study\": [\"Child\", \"Adult\", \"Older Adult\", \"...\"],\n",
        "      \"performance_status\": \"Karnofsky/Lansky â‰¥70%\",\n",
        "      \"disease_characteristics\": \"Histologically documented Ewing sarcoma as molecularly defined by...\",\n",
        "      \"body_weight_criteria\": \"patients must be â‰¥40 kg...\",\n",
        "      \"other_inclusion_criteria\": [\n",
        "        \"Adequate bone marrow function: ANC â‰¥ 1500/mm3...\",\n",
        "        \"Adequate renal function: eGFR rate â‰¥ 60 mL/min/1.73m2...\"\n",
        "      ]\n",
        "    }}\n",
        "\n",
        "    Only output the JSON object.\"\"\"\n",
        ")\n"
      ],
      "metadata": {
        "id": "BSAUOY1jsmv8"
      },
      "execution_count": null,
      "outputs": []
    },
    {
      "cell_type": "code",
      "source": [
        "# --- Run Preprocessing Agent (Step 2 Example) ---\n",
        "nct_id = \"NCT05275426\"\n",
        "trial_title = \"A Phase II Study of Oral CHK1 Inhibitor LY2880070 in Combination With Low-Dose Gemcitabine in Patients With Relapsed or Refractory Ewing Sarcoma, Ewing-like Sarcoma, and Desmoplastic Small Round Cell Tumor\"\n",
        "\n",
        "preprocessing_query = f\"Parse the full eligibility criteria for ClinicalTrials.gov ID: {nct_id} and convert it to the unified JSON format.\"\n",
        "print(f\"--- Running Preprocessing Agent for {nct_id} ---\")\n",
        "preprocessing_result = preprocessing_agent.run(preprocessing_query)\n",
        "print(preprocessing_result)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 1000
        },
        "id": "8Tvv4JaxuL25",
        "outputId": "a38b94a1-b9d7-49e6-af1b-48a751fb2d3f"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "--- Running Preprocessing Agent for NCT05275426 ---\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[38;2;212;183;2mâ•­â”€\u001b[0m\u001b[38;2;212;183;2mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[38;2;212;183;2m \u001b[0m\u001b[1;38;2;212;183;2mNew run\u001b[0m\u001b[38;2;212;183;2m \u001b[0m\u001b[38;2;212;183;2mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[38;2;212;183;2mâ”€â•®\u001b[0m\n",
              "\u001b[38;2;212;183;2mâ”‚\u001b[0m                                                                                                                 \u001b[38;2;212;183;2mâ”‚\u001b[0m\n",
              "\u001b[38;2;212;183;2mâ”‚\u001b[0m \u001b[1mParse the full eligibility criteria for ClinicalTrials.gov ID: NCT05275426 and convert it to the unified JSON \u001b[0m  \u001b[38;2;212;183;2mâ”‚\u001b[0m\n",
              "\u001b[38;2;212;183;2mâ”‚\u001b[0m \u001b[1mformat.\u001b[0m                                                                                                         \u001b[38;2;212;183;2mâ”‚\u001b[0m\n",
              "\u001b[38;2;212;183;2mâ”‚\u001b[0m                                                                                                                 \u001b[38;2;212;183;2mâ”‚\u001b[0m\n",
              "\u001b[38;2;212;183;2mâ•°â”€\u001b[0m\u001b[38;2;212;183;2m InferenceClientModel - Qwen/Qwen3-Next-80B-A3B-Thinking \u001b[0m\u001b[38;2;212;183;2mâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€\u001b[0m\u001b[38;2;212;183;2mâ”€â•¯\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #d4b702; text-decoration-color: #d4b702\">â•­â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ </span><span style=\"color: #d4b702; text-decoration-color: #d4b702; font-weight: bold\">New run</span><span style=\"color: #d4b702; text-decoration-color: #d4b702\"> â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•®</span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span>                                                                                                                 <span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span> <span style=\"font-weight: bold\">Parse the full eligibility criteria for ClinicalTrials.gov ID: NCT05275426 and convert it to the unified JSON </span>  <span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span> <span style=\"font-weight: bold\">format.</span>                                                                                                         <span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span>                                                                                                                 <span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”‚</span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702\">â•°â”€ InferenceClientModel - Qwen/Qwen3-Next-80B-A3B-Thinking â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â•¯</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[38;2;212;183;2mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â” \u001b[0m\u001b[1;37mStep 1\u001b[0m\u001b[38;2;212;183;2m â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â” </span><span style=\"color: #c0c0c0; text-decoration-color: #c0c0c0; font-weight: bold\">Step 1</span><span style=\"color: #d4b702; text-decoration-color: #d4b702\"> â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              " â”€ \u001b[1mExecuting parsed code:\u001b[0m â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34msearch_results\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;255;70;137;48;2;39;40;34m=\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34mweb_search\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m(\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34mquery\u001b[0m\u001b[38;2;255;70;137;48;2;39;40;34m=\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mNCT05275426\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m)\u001b[0m\u001b[48;2;39;40;34m                                                               \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34mprint\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m(\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34msearch_results\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m)\u001b[0m\u001b[48;2;39;40;34m                                                                                          \u001b[0m  \n",
              " â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"> â”€ <span style=\"font-weight: bold\">Executing parsed code:</span> â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">search_results </span><span style=\"color: #ff4689; text-decoration-color: #ff4689; background-color: #272822\">=</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\"> web_search(query</span><span style=\"color: #ff4689; text-decoration-color: #ff4689; background-color: #272822\">=</span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"NCT05275426\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">)</span><span style=\"background-color: #272822\">                                                               </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">print(search_results)</span><span style=\"background-color: #272822\">                                                                                          </span>  \n",
              " â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[1mExecution logs:\u001b[0m\n",
              "## Search Results\n",
              "\n",
              "[Study Details | NCT05275426 | A Study of LY2880070 and Gemcitabine in \n",
              "...](https://clinicaltrials.gov/study/NCT05275426)\n",
              "A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round \n",
              "Cell Tumor\n",
              "\n",
              "[Ewing sarcoma from molecular biology to the clinic - \n",
              "Frontiers](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1248753/\n",
              "full)\n",
              "A clinical trial was also initiated last year (ClinicalTrials.gov No. NCT05275426 ) to determine whether LY2880070,\n",
              "a Checkpoint kinase 1 (Chk1) inhibitor capable of regulating the G2/M transition of the cell cycle in combination \n",
              "with the chemotherapeutic agent gemcitabine could be an effective treatment for ES (Supplementary Table S2).\n",
              "\n",
              "[$150,000 Grant to MSK for New Ewing Sarcoma Combination \n",
              "Trial](https://www.littlewarrior.org/blog/2022/01/31/grant-to-msk-for-new-ewing-sarcoma-trial)\n",
              "Identifier: NCT05275426 For more information please reach out to the intake coordinators at MSK by calling \n",
              "833-MSK-KIDS, and reference Dr. Slotkin as lead PI and mention the new low-dose Gemcitabine & CHK1 Inhibition phase\n",
              "II clinical trial.\n",
              "\n",
              "[LY2880070 and Gemcitabine in Ewing Sarcoma and Ewing-Like ... - ICH \n",
              "GCP](https://ichgcp.net/clinical-trials-registry/NCT05275426)\n",
              "ICH GCP US Clinical Trials Registry Clinical Trial NCT05275426 A Study of LY2880070 and Gemcitabine in People With \n",
              "Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor\n",
              "\n",
              "[A Study of LY2880070 and Gemcitabine in People with Locally Advanced or \n",
              "...](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-02317)\n",
              "A Study of LY2880070 and Gemcitabine in People with Locally Advanced or Metastatic Ewing Sarcoma, Ewing-Like \n",
              "Sarcoma, or Desmoplastic Small Round Cell Tumor - NCT05275426 \n",
              "\n",
              "[A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing \n",
              "...](https://thancfoundation-org.clinicaltrialconnect.com/trials/NCT05275426)\n",
              "In addition to head & neck research studies, our archive highlights papers and book chapters. We cover topics like,\n",
              "the impact of treatments and rehabilitation on patients. Our lab focuses on developing treatments to improve the \n",
              "voice, speech, swallow functions and quality of life for patients. Surgery with or without radiation and \n",
              "chemoradiotherapy can cause changes to oral competence, speech ...\n",
              "\n",
              "[Trials Today](https://www.trialstoday.org/list/print/NCT05275426)\n",
              "More Details NCT ID NCT05275426 Status Recruiting Sponsor Memorial Sloan Kettering Cancer Center\n",
              "\n",
              "[Larvol Delta - A-Study-of-LY2880070-and-Gemcitabine-in-People-With \n",
              "...](https://delta.larvol.com/Institutions/231ee0c2b1be4d9e8eea64b2c139b50d/Esperas/6/a3c0f98fc310416dabff8f3391eff\n",
              "73e/A-Study-of-LY2880070-and-Gemcitabine-in-People-With-Ewing-Sarcoma-or-EwingLike-Sarcoma/)\n",
              "Feedback / Questions ESP-01 - Esperas gemcitabine - Generic mfg. http://clinicaltrials.gov/ct2/show/ NCT05275426 \n",
              "\n",
              "[Gemcitabine Recruiting Phase 2 Trials for Ewing's Sarcoma \n",
              "Treatment](https://go.drugbank.com/drugs/DB00441/clinical_trials?conditions=DBCOND0028085&phase=2&purpose=treatment\n",
              "&status=recruiting)\n",
              "Gemcitabine Recruiting Phase 2 Trials for Ewing's Sarcoma Treatment\n",
              "\n",
              "[Targeting DNA repair mechanisms in cancer therapy: the role of small \n",
              "...](https://academic.oup.com/narcancer/article/7/4/zcaf040/8313449)\n",
              "Separately, NCT05275426 is a Phase II clinical trial evaluating the safety and preliminary efficacy of the oral \n",
              "CHK1 inhibitor LY2880070 in combination with low-dose intravenous gemcitabine for patients with relapsed or \n",
              "refractory Ewing sarcoma, Ewing-like sarcoma, or desmoplastic small round cell tumor ( NCT05275426 ) [155].\n",
              "\n",
              "Out: None\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"font-weight: bold\">Execution logs:</span>\n",
              "## Search Results\n",
              "\n",
              "[Study Details | NCT05275426 | A Study of LY2880070 and Gemcitabine in \n",
              "...](https://clinicaltrials.gov/study/NCT05275426)\n",
              "A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round \n",
              "Cell Tumor\n",
              "\n",
              "[Ewing sarcoma from molecular biology to the clinic - \n",
              "Frontiers](https://www.frontiersin.org/journals/cell-and-developmental-biology/articles/10.3389/fcell.2023.1248753/\n",
              "full)\n",
              "A clinical trial was also initiated last year (ClinicalTrials.gov No. NCT05275426 ) to determine whether LY2880070,\n",
              "a Checkpoint kinase 1 (Chk1) inhibitor capable of regulating the G2/M transition of the cell cycle in combination \n",
              "with the chemotherapeutic agent gemcitabine could be an effective treatment for ES (Supplementary Table S2).\n",
              "\n",
              "[$150,000 Grant to MSK for New Ewing Sarcoma Combination \n",
              "Trial](https://www.littlewarrior.org/blog/2022/01/31/grant-to-msk-for-new-ewing-sarcoma-trial)\n",
              "Identifier: NCT05275426 For more information please reach out to the intake coordinators at MSK by calling \n",
              "833-MSK-KIDS, and reference Dr. Slotkin as lead PI and mention the new low-dose Gemcitabine &amp; CHK1 Inhibition phase\n",
              "II clinical trial.\n",
              "\n",
              "[LY2880070 and Gemcitabine in Ewing Sarcoma and Ewing-Like ... - ICH \n",
              "GCP](https://ichgcp.net/clinical-trials-registry/NCT05275426)\n",
              "ICH GCP US Clinical Trials Registry Clinical Trial NCT05275426 A Study of LY2880070 and Gemcitabine in People With \n",
              "Ewing Sarcoma,Ewing-Like Sarcoma, and Desmoplastic Small Round Cell Tumor\n",
              "\n",
              "[A Study of LY2880070 and Gemcitabine in People with Locally Advanced or \n",
              "...](https://www.cancer.gov/research/participate/clinical-trials-search/v?id=NCI-2022-02317)\n",
              "A Study of LY2880070 and Gemcitabine in People with Locally Advanced or Metastatic Ewing Sarcoma, Ewing-Like \n",
              "Sarcoma, or Desmoplastic Small Round Cell Tumor - NCT05275426 \n",
              "\n",
              "[A Study of LY2880070 and Gemcitabine in People With Ewing Sarcoma,Ewing \n",
              "...](https://thancfoundation-org.clinicaltrialconnect.com/trials/NCT05275426)\n",
              "In addition to head &amp; neck research studies, our archive highlights papers and book chapters. We cover topics like,\n",
              "the impact of treatments and rehabilitation on patients. Our lab focuses on developing treatments to improve the \n",
              "voice, speech, swallow functions and quality of life for patients. Surgery with or without radiation and \n",
              "chemoradiotherapy can cause changes to oral competence, speech ...\n",
              "\n",
              "[Trials Today](https://www.trialstoday.org/list/print/NCT05275426)\n",
              "More Details NCT ID NCT05275426 Status Recruiting Sponsor Memorial Sloan Kettering Cancer Center\n",
              "\n",
              "[Larvol Delta - A-Study-of-LY2880070-and-Gemcitabine-in-People-With \n",
              "...](https://delta.larvol.com/Institutions/231ee0c2b1be4d9e8eea64b2c139b50d/Esperas/6/a3c0f98fc310416dabff8f3391eff\n",
              "73e/A-Study-of-LY2880070-and-Gemcitabine-in-People-With-Ewing-Sarcoma-or-EwingLike-Sarcoma/)\n",
              "Feedback / Questions ESP-01 - Esperas gemcitabine - Generic mfg. http://clinicaltrials.gov/ct2/show/ NCT05275426 \n",
              "\n",
              "[Gemcitabine Recruiting Phase 2 Trials for Ewing's Sarcoma \n",
              "Treatment](https://go.drugbank.com/drugs/DB00441/clinical_trials?conditions=DBCOND0028085&amp;phase=2&amp;purpose=treatment\n",
              "&amp;status=recruiting)\n",
              "Gemcitabine Recruiting Phase 2 Trials for Ewing's Sarcoma Treatment\n",
              "\n",
              "[Targeting DNA repair mechanisms in cancer therapy: the role of small \n",
              "...](https://academic.oup.com/narcancer/article/7/4/zcaf040/8313449)\n",
              "Separately, NCT05275426 is a Phase II clinical trial evaluating the safety and preliminary efficacy of the oral \n",
              "CHK1 inhibitor LY2880070 in combination with low-dose intravenous gemcitabine for patients with relapsed or \n",
              "refractory Ewing sarcoma, Ewing-like sarcoma, or desmoplastic small round cell tumor ( NCT05275426 ) [155].\n",
              "\n",
              "Out: None\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[2m[Step 1: Duration 58.02 seconds| Input tokens: 2,446 | Output tokens: 9,497]\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">[Step 1: Duration 58.02 seconds| Input tokens: 2,446 | Output tokens: 9,497]</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[38;2;212;183;2mâ”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â” \u001b[0m\u001b[1;37mStep 2\u001b[0m\u001b[38;2;212;183;2m â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #d4b702; text-decoration-color: #d4b702\">â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â” </span><span style=\"color: #c0c0c0; text-decoration-color: #c0c0c0; font-weight: bold\">Step 2</span><span style=\"color: #d4b702; text-decoration-color: #d4b702\"> â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”â”</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              " â”€ \u001b[1mExecuting parsed code:\u001b[0m â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34mfinal_answer\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m(\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m{\u001b[0m\u001b[48;2;39;40;34m                                                                                                 \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34m  \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mclinical_trials_id\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m:\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mNCT05275426\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m,\u001b[0m\u001b[48;2;39;40;34m                                                                         \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34m  \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mtitle\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m:\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mA Phase II Study of Oral CHK1 Inhibitor LY2880070 in Combination With Low-Dose Gemcitabine in \u001b[0m\u001b[48;2;39;40;34m     \u001b[0m  \n",
              "  \u001b[38;2;230;219;116;48;2;39;40;34mPatients With Relapsed or Refractory Ewing Sarcoma, Ewing-like Sarcoma, and Desmoplastic Small Round Cell \u001b[0m\u001b[48;2;39;40;34m     \u001b[0m  \n",
              "  \u001b[38;2;230;219;116;48;2;39;40;34mTumor\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m,\u001b[0m\u001b[48;2;39;40;34m                                                                                                        \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34m  \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mages_eligible_for_study\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m:\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m[\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mChild\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m,\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mAdult\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m]\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m,\u001b[0m\u001b[48;2;39;40;34m                                                               \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34m  \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mperformance_status\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m:\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mKarnofsky/Lansky â‰¥70\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m%\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m,\u001b[0m\u001b[48;2;39;40;34m                                                               \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34m  \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mdisease_characteristics\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m:\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mHistologically documented Ewing sarcoma as molecularly defined by EWSR1 gene \u001b[0m\u001b[48;2;39;40;34m    \u001b[0m  \n",
              "  \u001b[38;2;230;219;116;48;2;39;40;34mrearrangement\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m,\u001b[0m\u001b[48;2;39;40;34m                                                                                                \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34m  \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mbody_weight_criteria\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m:\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mpatients must be â‰¥40 kg\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m,\u001b[0m\u001b[48;2;39;40;34m                                                           \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34m  \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mother_inclusion_criteria\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m:\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m \u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m[\u001b[0m\u001b[48;2;39;40;34m                                                                                \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34m    \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mAdequate bone marrow function: ANC â‰¥ 1500/mm3, platelets â‰¥ 100,000/mm3\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m,\u001b[0m\u001b[48;2;39;40;34m                                  \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34m    \u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34mAdequate renal function: eGFR rate â‰¥ 60 mL/min/1.73m2\u001b[0m\u001b[38;2;230;219;116;48;2;39;40;34m\"\u001b[0m\u001b[48;2;39;40;34m                                                    \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34m  \u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m]\u001b[0m\u001b[48;2;39;40;34m                                                                                                            \u001b[0m  \n",
              "  \u001b[38;2;248;248;242;48;2;39;40;34m}\u001b[0m\u001b[38;2;248;248;242;48;2;39;40;34m)\u001b[0m\u001b[48;2;39;40;34m                                                                                                             \u001b[0m  \n",
              " â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"> â”€ <span style=\"font-weight: bold\">Executing parsed code:</span> â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">final_answer({</span><span style=\"background-color: #272822\">                                                                                                 </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">  </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"clinical_trials_id\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">: </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"NCT05275426\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">,</span><span style=\"background-color: #272822\">                                                                         </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">  </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"title\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">: </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"A Phase II Study of Oral CHK1 Inhibitor LY2880070 in Combination With Low-Dose Gemcitabine in </span><span style=\"background-color: #272822\">     </span>  \n",
              "  <span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">Patients With Relapsed or Refractory Ewing Sarcoma, Ewing-like Sarcoma, and Desmoplastic Small Round Cell </span><span style=\"background-color: #272822\">     </span>  \n",
              "  <span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">Tumor\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">,</span><span style=\"background-color: #272822\">                                                                                                        </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">  </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"ages_eligible_for_study\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">: [</span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"Child\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">, </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"Adult\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">],</span><span style=\"background-color: #272822\">                                                               </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">  </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"performance_status\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">: </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"Karnofsky/Lansky â‰¥70%\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">,</span><span style=\"background-color: #272822\">                                                               </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">  </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"disease_characteristics\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">: </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"Histologically documented Ewing sarcoma as molecularly defined by EWSR1 gene </span><span style=\"background-color: #272822\">    </span>  \n",
              "  <span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">rearrangement\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">,</span><span style=\"background-color: #272822\">                                                                                                </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">  </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"body_weight_criteria\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">: </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"patients must be â‰¥40 kg\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">,</span><span style=\"background-color: #272822\">                                                           </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">  </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"other_inclusion_criteria\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">: [</span><span style=\"background-color: #272822\">                                                                                </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">    </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"Adequate bone marrow function: ANC â‰¥ 1500/mm3, platelets â‰¥ 100,000/mm3\"</span><span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">,</span><span style=\"background-color: #272822\">                                  </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">    </span><span style=\"color: #e6db74; text-decoration-color: #e6db74; background-color: #272822\">\"Adequate renal function: eGFR rate â‰¥ 60 mL/min/1.73m2\"</span><span style=\"background-color: #272822\">                                                    </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">  ]</span><span style=\"background-color: #272822\">                                                                                                            </span>  \n",
              "  <span style=\"color: #f8f8f2; text-decoration-color: #f8f8f2; background-color: #272822\">})</span><span style=\"background-color: #272822\">                                                                                                             </span>  \n",
              " â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€ \n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"></pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[1;38;2;212;183;2mFinal answer: {'clinical_trials_id': 'NCT05275426', 'title': 'A Phase II Study of Oral CHK1 Inhibitor LY2880070 in \u001b[0m\n",
              "\u001b[1;38;2;212;183;2mCombination With Low-Dose Gemcitabine in Patients With Relapsed or Refractory Ewing Sarcoma, Ewing-like Sarcoma, \u001b[0m\n",
              "\u001b[1;38;2;212;183;2mand Desmoplastic Small Round Cell Tumor', 'ages_eligible_for_study': ['Child', 'Adult'], 'performance_status': \u001b[0m\n",
              "\u001b[1;38;2;212;183;2m'Karnofsky/Lansky â‰¥70%', 'disease_characteristics': 'Histologically documented Ewing sarcoma as molecularly defined\u001b[0m\n",
              "\u001b[1;38;2;212;183;2mby EWSR1 gene rearrangement', 'body_weight_criteria': 'patients must be â‰¥40 kg', 'other_inclusion_criteria': \u001b[0m\n",
              "\u001b[1;38;2;212;183;2m['Adequate bone marrow function: ANC â‰¥ 1500/mm3, platelets â‰¥ 100,000/mm3', 'Adequate renal function: eGFR rate â‰¥ 60\u001b[0m\n",
              "\u001b[1;38;2;212;183;2mmL/min/1.73m2']}\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #d4b702; text-decoration-color: #d4b702; font-weight: bold\">Final answer: {'clinical_trials_id': 'NCT05275426', 'title': 'A Phase II Study of Oral CHK1 Inhibitor LY2880070 in </span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702; font-weight: bold\">Combination With Low-Dose Gemcitabine in Patients With Relapsed or Refractory Ewing Sarcoma, Ewing-like Sarcoma, </span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702; font-weight: bold\">and Desmoplastic Small Round Cell Tumor', 'ages_eligible_for_study': ['Child', 'Adult'], 'performance_status': </span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702; font-weight: bold\">'Karnofsky/Lansky â‰¥70%', 'disease_characteristics': 'Histologically documented Ewing sarcoma as molecularly defined</span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702; font-weight: bold\">by EWSR1 gene rearrangement', 'body_weight_criteria': 'patients must be â‰¥40 kg', 'other_inclusion_criteria': </span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702; font-weight: bold\">['Adequate bone marrow function: ANC â‰¥ 1500/mm3, platelets â‰¥ 100,000/mm3', 'Adequate renal function: eGFR rate â‰¥ 60</span>\n",
              "<span style=\"color: #d4b702; text-decoration-color: #d4b702; font-weight: bold\">mL/min/1.73m2']}</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "\u001b[2m[Step 2: Duration 54.04 seconds| Input tokens: 6,180 | Output tokens: 19,512]\u001b[0m\n"
            ],
            "text/html": [
              "<pre style=\"white-space:pre;overflow-x:auto;line-height:normal;font-family:Menlo,'DejaVu Sans Mono',consolas,'Courier New',monospace\"><span style=\"color: #7f7f7f; text-decoration-color: #7f7f7f\">[Step 2: Duration 54.04 seconds| Input tokens: 6,180 | Output tokens: 19,512]</span>\n",
              "</pre>\n"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "{'clinical_trials_id': 'NCT05275426', 'title': 'A Phase II Study of Oral CHK1 Inhibitor LY2880070 in Combination With Low-Dose Gemcitabine in Patients With Relapsed or Refractory Ewing Sarcoma, Ewing-like Sarcoma, and Desmoplastic Small Round Cell Tumor', 'ages_eligible_for_study': ['Child', 'Adult'], 'performance_status': 'Karnofsky/Lansky â‰¥70%', 'disease_characteristics': 'Histologically documented Ewing sarcoma as molecularly defined by EWSR1 gene rearrangement', 'body_weight_criteria': 'patients must be â‰¥40 kg', 'other_inclusion_criteria': ['Adequate bone marrow function: ANC â‰¥ 1500/mm3, platelets â‰¥ 100,000/mm3', 'Adequate renal function: eGFR rate â‰¥ 60 mL/min/1.73m2']}\n"
          ]
        }
      ]
    }
  ]
}